Skip to main content

Advertisement

SpringerLink
Log in

Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

An Erratum to this article was published on 18 February 2016

Abstract

Incretin hormones have been reported to have cytoprotective actions in addition to their glucose-lowering effects. We evaluated whether teneligliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, affects left ventricular (LV) function in patients with type 2 diabetes mellitus (T2DM). Twenty-nine T2DM patients not receiving any incretin-based drugs were enrolled and prescribed with teneligliptin for 3 months. Compared to baseline levels, hemoglobin A1c levels decreased (7.6 ± 1.0 % to 6.9 ± 0.7 %, p < 0.01) and 1,5-anhydro-d-glucitol levels increased (9.6 ± 7.2 μg/mL to 13.5 ± 8.7 μg/mL, p < 0.01) after treatment. Clinical parameters, including body mass index and blood pressure, did not show any difference before and after treatment. Three months after treatment, there were improvements in LV systolic and diastolic function [LV ejection fraction, 62.0 ± 6.5 % to 64.5 ± 5.0 %, p = 0.01; peak early diastolic velocity/basal septal diastolic velocity (E/e′) ratio, 13.3 ± 4.1 to 11.9 ± 3.3, p = 0.01]. Moreover, there was an improvement in endothelial function (reactive hyperemia peripheral arterial tonometry [RH-PAT] index; 1.58 ± 0.47 to 2.01 ± 0.72, p < 0.01). There was a significant negative correlation between changes in the E/e’ ratio and RH-PAT values. Furthermore, circulating adiponectin levels increased (27.0 ± 38.5 pg/mL to 42.7 ± 33.2 pg/mL, p < 0.01) without changes in patient body weight. Teneligliptin treatment was associated with improvements in LV function and endothelial functions, and an increase in serum adiponectin levels. These results support the cardio-protective effects of teneligliptin in T2DM patients and increase in serum adiponectin levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP (2008) Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 10:1212–1220

    CAS  PubMed  Google Scholar 

  2. Deacon CF (2011) Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 13:7–18

    Article  CAS  PubMed  Google Scholar 

  3. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340–2350

    Article  CAS  PubMed  Google Scholar 

  4. Monji A, Mitsui T, Bando YK, Aoyama M, Shigeta T, Murohara T (2013) Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am J Physiol Heart Circ Physiol 305:H295–H304

    Article  CAS  PubMed  Google Scholar 

  5. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, Hussein MA (2011) Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifelink database. Diabetes Care 34:90–95

    Article  CAS  PubMed  Google Scholar 

  6. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S, De Meester I (2006) Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 52:82–87

    Article  CAS  PubMed  Google Scholar 

  7. Gomez N, Matheeussen V, Damoiseaux C, Tamborini A, Merveille AC, Jespers P, Michaux C, Clercx C, De Meester I, Mc Entee K (2012) Effect of heart failure on dipeptidyl peptidase IV activity in plasma of dogs. J Vet Intern Med 26:929–934

    Article  CAS  PubMed  Google Scholar 

  8. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326

    Article  CAS  PubMed  Google Scholar 

  9. Ussher JR, Drucker DJ (2012) Cardiovascular biology of the incretin system. Endocr Rev 33:187–215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H (2013) Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 77:1337–1344

    Article  CAS  PubMed  Google Scholar 

  11. Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S, Chattipakorn N (2013) Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol 167:451–457

    Article  PubMed  Google Scholar 

  12. Nogueira KC, Furtado M, Fukui RT, Correia MR, Dos Santos RF, Andrade JL, Rossi da Silva ME (2014) Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study. Diabetol Metab Syndr 6:103

    Article  PubMed  PubMed Central  Google Scholar 

  13. Fujiwara T, Yoshida M, Nakamura T, Sakakura K, Wada H, Arao K, Katayama T, Funayama H, Sugawara Y, Mitsuhashi T, Kakei M, Momomura SI, Ako J (2014) Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients. Heart Vessels. doi:10.1007/s00380-014-0509-4

    Google Scholar 

  14. McCormick LM, Kydd AC, Read PA, Ring LS, Bond SJ, Hoole SP, Dutka DP (2014) Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circ Cardiovasc Imaging 7:274–281

    Article  PubMed  Google Scholar 

  15. Mori Y, Taniguchi Y, Matsuura K, Sezaki K, Yokoyama J, Utsunomiya K (2011) Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. Diabetes Technol Ther 13:699–703

    Article  CAS  PubMed  Google Scholar 

  16. Goda M, Kadowaki T (2013) Teneligliptin for the treatment of type 2 diabetes. Drugs Today (Barc) 49:615–629

    CAS  Google Scholar 

  17. Kadowaki T, Kondo K (2014) Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab 16:418–425

    Article  CAS  PubMed  Google Scholar 

  18. Kadowaki T, Kondo K (2013) Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 4:576–584

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Otsuki H, Kosaka T, Nakamura K, Shimomura F, Kuwahara Y, Tsukamoto T (2014) Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. Int Urol Nephrol 46:427–432

    Article  CAS  PubMed  Google Scholar 

  20. Tanaka S, Suzuki K, Aoki C, Niitani M, Kato K, Tomotsune T, Aso Y (2014) Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. Diabetes Technol Ther 16(12):840–845

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Matsuzawa Y, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Konishi M, Matsubara J, Sumida H, Kaikita K, Kojima S, Nagayoshi Y, Yamamuro M, Izumiya Y, Iwashita S, Matsui K, Jinnouchi H, Kimura K, Umemura S, Ogawa H (2010) Digital assessment of endothelial function and ischemic heart disease in women. J Am Coll Cardiol 55:1688–1696

    Article  PubMed  Google Scholar 

  22. Bonetti PO, Barsness GW, Keelan PC, Schnell TI, Pumper GM, Kuvin JT, Schnall RP, Holmes DR, Higano ST, Lerman A (2003) Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 41(10):1761–1768

    Article  PubMed  Google Scholar 

  23. Kume T, Akasaka T, Kawamoto T, Ogasawara Y, Watanabe N, Toyota E, Neishi Y, Sukmawan R, Sadahira Y, Yoshida K (2006) Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol 97:1713–1717

    Article  PubMed  Google Scholar 

  24. Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G, Galderisi M, Marwick T, Nagueh SF, Sengupta PP, Sicari R, Smiseth OA, Smulevitz B, Takeuchi M, Thomas JD, Vannan M, Voigt JU, Zamorano JL (2011) Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr 24:277–313

    Article  PubMed  Google Scholar 

  25. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ (2000) Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 102:1788–1794

    Article  CAS  PubMed  Google Scholar 

  26. Cosson S, Kevorkian JP (2003) Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab 29:455–466

    Article  CAS  PubMed  Google Scholar 

  27. Cohn JN, Johnson G (1990) Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group. Circulation 81:Iii48–Iii53

    Article  CAS  PubMed  Google Scholar 

  28. Neglia D, Michelassi C, Trivieri MG, Sambuceti G, Giorgetti A, Pratali L, Gallopin M, Salvadori P, Sorace O, Carpeggiani C, Poddighe R, L’Abbate A, Parodi O (2002) Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 105:186–193

    Article  PubMed  Google Scholar 

  29. Shida T, Nozawa T, Sobajima M, Ihori H, Matsuki A, Inoue H (2014) Fluvastatin-induced reduction of oxidative stress ameliorates diabetic cardiomyopathy in association with improving coronary microvasculature. Heart Vessels. doi:10.1007/s00380-013-0402-6

    PubMed  Google Scholar 

  30. Kishida K, Funahashi T, Shimomura I (2012) Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. Endocr Metab Immune Disord Drug Targets 12:118–131

    Article  CAS  PubMed  Google Scholar 

  31. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737

    Article  CAS  PubMed  Google Scholar 

  32. Kishida K, Funahashi T, Shimomura I (2014) Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab 28:119–130

    Article  CAS  PubMed  Google Scholar 

  33. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D’Angelo A, Cicero AF (2010) Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 59:887–895

    Article  CAS  PubMed  Google Scholar 

  34. Hibuse T, Maeda N, Kishida K, Kimura T, Minami T, Takeshita E, Hirata A, Nakagawa Y, Kashine S, Oka A, Hayashi M, Nishizawa H, Funahashi T, Shimomura I (2014) A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus–a randomized controlled trial START-J study. Cardiovasc Diabetol 13:96

    Article  PubMed  PubMed Central  Google Scholar 

  35. Shestakova MV, Suhareva OIu, Chernova TO, Shmushkovich IA, Aleksandrov AA, Il’in AV, Dedov II (2013) A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition. Ter Arkh 85:49–55

    CAS  PubMed  Google Scholar 

  36. Li L, Yang G, Li Q, Tan X, Liu H, Tang Y, Boden G (2008) Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes Metab 10(10):921–930

    Article  CAS  PubMed  Google Scholar 

  37. Kim Chung le T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, Nakaya Y (2009) Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 390:613–618

    Article  PubMed  Google Scholar 

  38. Diaz-Soto G, de Luis DA, Conde-Vicente R, Izaola-Jauregui O, Ramos C, Romero E (2014) Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study. Diabetes Res Clin Pract 104:92–96

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We appreciate the assistance from Ms. Kazumi Nakazato, the technical assistant in the Department of Cardiovascular Medicine, Kitasato University School of Medicine.

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan

    Takehiro Hashikata, Ryota Kakizaki, Teruyoshi Nemoto, Kazuhiro Fujiyoshi, Sayaka Namba, Lisa Kitasato, Takuya Hashimoto, Ryo Kameda, Emi Maekawa, Takao Shimohama, Taiki Tojo & Junya Ako

  2. Department of Rehabilitation, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan

    Minako Yamaoka-Tojo

Authors
  1. Takehiro Hashikata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Minako Yamaoka-Tojo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryota Kakizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teruyoshi Nemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuhiro Fujiyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sayaka Namba
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lisa Kitasato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takuya Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ryo Kameda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Emi Maekawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takao Shimohama
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Taiki Tojo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Junya Ako
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takehiro Hashikata.

Ethics declarations

Conflict of interest

This study was partly supported by International Grants-in-Aid for Research from the Kitasato University School of Allied Health Sciences, Daiichi-Sankyo, MSD K.K., Bayer Pharma, Tanabe Mitsubishi, and Boehringer Ingelheim (M. Y–T.). Dr. Junya Ako received speaking honorarium from Tanabe Mitsubishi, Daiichi-Sankyo, MSD K.K., Boehringer Ingelheim, Kowa, and Kyowa Hakko Kirin. The other authors have nothing to disclose regarding this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hashikata, T., Yamaoka-Tojo, M., Kakizaki, R. et al. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes. Heart Vessels 31, 1303–1310 (2016). https://doi.org/10.1007/s00380-015-0724-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-015-0724-7

Keywords

Search

Navigation